New possibilities of radionuclide therapy for patients with castration-resistant prostate cancer with bone metastases. The first experience of using radium-223 at the Chelyabinsk Regional Clinical Center for Oncology and Nuclear Medicine
- Authors: Vasilieva E.B.1,2, Tolpeykina K.A1, Vazhenin A.V1,2, Chvanova K.V1
-
Affiliations:
- helyabinsk Regional Clinical Center for Oncology and Nuclear Medicine
- South Ural State Medical University
- Issue: Vol 27, No 11 (2020)
- Pages: 55-58
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312877
- DOI: https://doi.org/10.18565/pharmateca.2020.11.55-58
- ID: 312877
Cite item
Abstract
Full Text
![Restricted Access](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
About the authors
Ekaterina B. Vasilieva
helyabinsk Regional Clinical Center for Oncology and Nuclear Medicine; South Ural State Medical University
Email: v_kat@rambler.ru
Cand. Sci. (Med.), Head of the Radiotherapeutic Department of Systemic Therapy 42, Blyukher str., Chelyabinsk 454087, Russian Federation
K. A Tolpeykina
helyabinsk Regional Clinical Center for Oncology and Nuclear MedicineChelyabinsk, Russia
A. V Vazhenin
helyabinsk Regional Clinical Center for Oncology and Nuclear Medicine; South Ural State Medical UniversityChelyabinsk, Russia
K. V Chvanova
helyabinsk Regional Clinical Center for Oncology and Nuclear MedicineChelyabinsk, Russia
References
- Mattiuzzi C., Lippi G. Current Cancer Epidemiology. J Epidemiol Glob Health. 2019;9(4):217-22. doi: 10.2991/jegh.k.191008.001.
- Bray F, Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424. doi: 10.3322/caac.21492.
- Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). Под ред. Каприна А.Д., Старинского В.В., Петровой Г В. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019. 250 с.
- Noguchi M, Kikuchi H., Ishibashi M., et al. Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer. Br J Cancer. 2003;88(2):195-201. doi: 10.1038/sj.bjc.6600715.
- Scher H, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187-97. Doi: 10.1056/ NEJMoa1207506.
- Васильева Е.Б., Важенин А.В., Гелиашвили Т. М., Сырчикова Е.А.Эффективность стронция-89 хлорид в купировании болевого синдрома у больных с костными метастазами различных опухолей. Паллиативная медицина и реабилитация. 2016;1:21-5.
- Parker C., Nilsson S., Heinrich D., et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213-23. doi: 10.1056/NEJMoa1213755.
- Sartor O., Coleman R., Nilsson S., et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014;15(7);738-46. doi: 10.1016/S1470-2045(14)70183-4.
- Parker C., Finkelstein S.E., MichalskiJ.M., et al. Efficacy and safety of radium-223 dichloride in symptomatic castration-resistant prostate cancer patients with or without baseline opioid use from the phase 3 ALSYMPCA trial. Eur Urol. 2016;70(5):875-83. doi: 10.1016/j.eururo.2016.06.002.
- Saad F., Carles J., Gillessen S., et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol. 2016;17(9):1306-16. Doi: 10.1016/ S1470-2045(16)30173-5.
- Porter A.T., McEwan A.J., Powe I.E., et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol. 1993;25(5):805-13. doi: 10.1016/0360-3016(93)90309-j.
- Cheetham P.J., Petrylak D.E! Alpha particles as radiopharmaceuticals in the treatment of bone metastases: mechanism of action of radium-223 chloride (Alpharadin) and radiation protection. Oncology. 2012;26(4):330-37.
- Nilsson S. Radium-223 dichloride for the treatment of bone metastatic castrationresistant prostate cancer: an evaluation of its safety. Expert Opin Drug Saf. 2015;14(7):1127-36. doi: 10.1517/14740338.2015.1045874.
- Carrasquillo J.A., O'Donoghue J.A., Pandit-Taskar N., et al. Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40(9):1384-93. Doi: 10.1007/ s00259-013-2427-6.
Supplementary files
![](/img/style/loading.gif)